Q2 FY2026 EarningsQ2 FY26 missed consensus significantly on the bottom line due to a one-time $200M royalty buyout. Net loss of $241.1M ($2.85 per share) was far wider than the expected $46.3M loss ($0.55 per share). Despite the earnings miss, strategic financing and the PDUFA target date of December 22, 2026, for lorundrostat remain the primary focus, with a strengthened balance sheet of $661.4M in cash to support commercial launch.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Mineralys Therapeutics(MLYS) the EBIT is -246.04 M (-426.3%), Miss estimate;the EPS is -2.85 (-331.8%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.25B426.33%
-0.05B4.10%
-0.20B422.23%
EPSMiss expectations
-2.85331.82%
-0.548616.88%
-2.3014348.70%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf